Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Schöffski, Patrick; Woźniak, Agnieszka; Stacchiotti, Silvia; Rutkowski, Piotr; Blay, Jean‐Yves; Линднер, Ларс; Strauss, Sandra J.; Anthoney, Alan; Duffaud, Florence; Richter, Stephan; Grünwald, Viktor; Leahy, Michael; Reichardt, Peter; Šufliarský, Jozef; Graaf, Winette Ta van der; Sciot, Raf; Dębiec‐Rychter, Maria; Cann, Thomas Van; Marréaud, Sandrine; Lia, Michela; Raveloarivahy, Tiana; Collette, Laurence; Bauer, Sebastian

doi:10.1093/annonc/mdx527

Cited by 80 publications

(43 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prospective clinical trial of an ALK inhibitor to treat rhabdomyosarcoma did not show clinical meaningful efficacy [108]. On the other hand, crizotinib, an ALK inhibitor which has been investigated to rhabodmyosarcoma with ALK expression above, is known as inhibiting other targets such as MET, and showed some clinical responses to clear cell sarcomas overexpressing MET [109]. For rare diseases, rare mutation-targeted therapies are pursued, and the importance of detecting targeted mutations precisely (including mutation types) is greater; the risk of misdiagnosis should also be considered [110].…”

Section: Whole-genome Sequencing For Precision Medicine For Sts Patientsmentioning

confidence: 99%

Precision Medicine in Soft Tissue Sarcoma Treatment

Nakano

Takahashi

2020

Cancers

View full text Add to dashboard Cite

Soft tissue sarcoma (STS) is a rare component of malignant diseases. STS includes various histological subtypes, and there are some important differences among the different histological subtypes regarding the mutation profile and sensitivity to antitumor agents. Many clinical trials of STS incorporating many different histological subtypes in various populations have been conducted; it is difficult to compare the findings and make conclusions about clinical efficacy. Targeted therapies focusing on specific histological subtypes and precision therapy focusing on the specific genetic mutation(s) of each STS patient are being investigated. Since STS patients are a small population, new clinical trial designs are required to evaluate and establish new targeted therapies for each histological subtype that has a limited number of patients, and preclinical investigations are needed to detect targetable mutations. Now that cancer genome profiling is used in clinical practice, it is urgently necessary to connect the genome profiling data obtained in clinical settings to the optimal clinical treatment strategies. Herein we review the development and challenges of precision therapy in the management of STS patients.

show abstract

Section: Whole-genome Sequencing For Precision Medicine For Sts Patientsmentioning

confidence: 99%

Precision Medicine in Soft Tissue Sarcoma Treatment

Nakano

Takahashi

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…The PFS with crizotinib in MET+ CCS was similar to results achieved with doxorubicin. 15 The NCT00557609, a phase 2 trial, has shown that disease control was obtained in 36% patients with tivantinib, a MET inhibitor. 16 Mir et al reported a case of metastatic CCS with myocardium metastasis.…”

Section: Discussionmentioning

confidence: 99%

Clear cell sarcoma of the esophagus: A rare location

Yahyaoui

Zenzri

Behi

et al. 2019

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…In unusual cases, additional diagnostic work-up such as molecular pathological investigations are necessary to determine rare differential diagnoses. Early diagnosis is particularly important for a favorable outcome of CCS [7,10]. We recommend the performance of FISH or fusion analyses for EWS gene rearrangements in patients with atypical clinical courses or wild type mutated MUP.…”

Section: Dear Editorsmentioning

confidence: 99%